Xeris Biopharma Holdings (XERS) Other Accumulated Expenses (2020 - 2026)

Xeris Biopharma Holdings has reported Other Accumulated Expenses for 7 years, with the latest figure at $4.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 85.84% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $4.4 million (down 85.84% YoY), and the FY2025 full-year result was $4.9 million, up 348.94% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $4.4 million, down from $4.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $30.7 million in Q1 2025, with the low at $619000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $9.5 million across 5 years, with a median of $4.4 million in 2026.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 20237.89% — and 2024, when it plunged 96.85%.
• Xeris Biopharma Holdings' Other Accumulated Expenses stood at $16.8 million in 2022, then jumped by 31.7% to $22.1 million in 2023, then tumbled by 95.08% to $1.1 million in 2024, then jumped by 348.94% to $4.9 million in 2025, then fell by 10.96% to $4.4 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.4 million (Q1 2026), $4.9 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.